Literature DB >> 30193298

Mechanisms of Cell-to-Cell Transmission of Pathological Tau: A Review.

Garrett S Gibbons1,2, Virginia M Y Lee1,2,3, John Q Trojanowski1,2,3.   

Abstract

Importance: Intracellular tau protein aggregates are a pathological hallmark of neurodegenerative tauopathies, including Alzheimer disease (AD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and Pick disease. Emerging evidence supports a model of cell-to-cell transmission of proteinaceous pathological tau seeds, which leads to recruitment and templated fibrillization of endogenous cellular tau followed by the spread of abnormal tau throughout the brain. These findings lead to the strain hypothesis, which predicts that distinct conformational strains or polymorphs of tau may underlie the clinical and neuropathological heterogeneity and cell-type specificity of tauopathies. In this review, we describe the evidence for propagation of distinct tau strains in cell culture and animal models of AD and mechanistic insights into cell-to-cell transmission of pathological tau. Observations: Intracranial injections of synthetic tau-preformed fibrils and human brain-derived pathological tau into nontransgenic wild-type mice and transgenic mouse models of AD expressing β-amyloid and tau-amyloid deposits yield widespread pathological tau aggregates observed in neuroanatomically connected brain regions distant from the site of injection. Furthermore, when human brain-derived pathological tau obtained from distinct tauopathies (ie, brains with AD, PSP, and CBD) were injected into the brains of wild-type mice, they seeded tau pathology and faithfully recapitulated cell-type specific tau inclusions characteristic of each tauopathy in a time-dependent, dose-dependent, and injection site-dependent spread reflective of the connectome of the injection site. Conclusions and Relevance: These findings provide compelling evidence that misfolded or pathological conformers of tau undergo cell-to-cell spread in a tauopathy strain-specific manner. Importantly, evidence to date supports that pathological tau strains do not behave like infectious agents, despite growing evidence that these tau strains undergo templated propagation and spread linked to the neuroanatomical connectome of the injection site.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30193298      PMCID: PMC6382549          DOI: 10.1001/jamaneurol.2018.2505

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  74 in total

1.  Selective imaging of internalized proteopathic α-synuclein seeds in primary neurons reveals mechanistic insight into transmission of synucleinopathies.

Authors:  Richard J Karpowicz; Conor M Haney; Tiberiu S Mihaila; Raizel M Sandler; E James Petersson; Virginia M-Y Lee
Journal:  J Biol Chem       Date:  2017-06-13       Impact factor: 5.157

2.  Proteopathic tau seeding predicts tauopathy in vivo.

Authors:  Brandon B Holmes; Jennifer L Furman; Thomas E Mahan; Tritia R Yamasaki; Hilda Mirbaha; William C Eades; Larisa Belaygorod; Nigel J Cairns; David M Holtzman; Marc I Diamond
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-26       Impact factor: 11.205

3.  Exosome-associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease.

Authors:  Sudad Saman; WonHee Kim; Mario Raya; Yvonne Visnick; Suhad Miro; Sarmad Saman; Bruce Jackson; Ann C McKee; Victor E Alvarez; Norman C Y Lee; Garth F Hall
Journal:  J Biol Chem       Date:  2011-11-04       Impact factor: 5.157

4.  Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression.

Authors:  Xiyun Chai; Su Wu; Tracey K Murray; Robert Kinley; Claire V Cella; Helen Sims; Nicola Buckner; Jenna Hanmer; Peter Davies; Michael J O'Neill; Michael L Hutton; Martin Citron
Journal:  J Biol Chem       Date:  2011-08-12       Impact factor: 5.157

5.  Tau protein concentrations in cerebrospinal fluid of patients with dementia of the Alzheimer type.

Authors:  R E Tato; A Frank; A Hernanz
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-09       Impact factor: 10.154

6.  Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

Authors:  M Vandermeeren; M Mercken; E Vanmechelen; J Six; A van de Voorde; J J Martin; P Cras
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

7.  Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17.

Authors:  M Hutton; C L Lendon; P Rizzu; M Baker; S Froelich; H Houlden; S Pickering-Brown; S Chakraverty; A Isaacs; A Grover; J Hackett; J Adamson; S Lincoln; D Dickson; P Davies; R C Petersen; M Stevens; E de Graaff; E Wauters; J van Baren; M Hillebrand; M Joosse; J M Kwon; P Nowotny; L K Che; J Norton; J C Morris; L A Reed; J Trojanowski; H Basun; L Lannfelt; M Neystat; S Fahn; F Dark; T Tannenberg; P R Dodd; N Hayward; J B Kwok; P R Schofield; A Andreadis; J Snowden; D Craufurd; D Neary; F Owen; B A Oostra; J Hardy; A Goate; J van Swieten; D Mann; T Lynch; P Heutink
Journal:  Nature       Date:  1998-06-18       Impact factor: 49.962

8.  C-Terminally Truncated Forms of Tau, But Not Full-Length Tau or Its C-Terminal Fragments, Are Released from Neurons Independently of Cell Death.

Authors:  Daniel Kanmert; Adam Cantlon; Christina R Muratore; Ming Jin; Tiernan T O'Malley; Gloria Lee; Tracy L Young-Pearse; Dennis J Selkoe; Dominic M Walsh
Journal:  J Neurosci       Date:  2015-07-29       Impact factor: 6.167

Review 9.  The Synucleinopathies: Twenty Years On.

Authors:  Michel Goedert; Ross Jakes; Maria Grazia Spillantini
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

10.  An Efficient Procedure for Removal and Inactivation of Alpha-Synuclein Assemblies from Laboratory Materials.

Authors:  Luc Bousset; Patrik Brundin; Anja Böckmann; Beat Meier; Ronald Melki
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

View more
  64 in total

1.  4-Repeat tau seeds and templating subtypes as brain and CSF biomarkers of frontotemporal lobar degeneration.

Authors:  Eri Saijo; Michael A Metrick; Shunsuke Koga; Piero Parchi; Irene Litvan; Salvatore Spina; Adam Boxer; Julio C Rojas; Douglas Galasko; Allison Kraus; Marcello Rossi; Kathy Newell; Gianluigi Zanusso; Lea T Grinberg; William W Seeley; Bernardino Ghetti; Dennis W Dickson; Byron Caughey
Journal:  Acta Neuropathol       Date:  2019-10-16       Impact factor: 17.088

Review 2.  Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain.

Authors:  Richard A Hickman; Xena E Flowers; Thomas Wisniewski
Journal:  Curr Neurol Neurosci Rep       Date:  2020-07-14       Impact factor: 5.081

3.  Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.

Authors:  Brian Spencer; Ivy Trinh; Edward Rockenstein; Michael Mante; Jazmin Florio; Anthony Adame; Omar M A El-Agnaf; Changyoun Kim; Eliezer Masliah; Robert A Rissman
Journal:  Neurobiol Dis       Date:  2019-03-05       Impact factor: 5.996

4.  Breakthroughs in antemortem diagnosis of neurodegenerative diseases.

Authors:  Glenn C Telling
Journal:  Proc Natl Acad Sci U S A       Date:  2019-10-30       Impact factor: 11.205

Review 5.  Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies.

Authors:  Che-Wei Chang; Eric Shao; Lennart Mucke
Journal:  Science       Date:  2021-02-26       Impact factor: 47.728

Review 6.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

Review 7.  It's all about tau.

Authors:  Cheril Tapia-Rojas; Fabian Cabezas-Opazo; Carol A Deaton; Erick H Vergara; Gail V W Johnson; Rodrigo A Quintanilla
Journal:  Prog Neurobiol       Date:  2018-12-31       Impact factor: 11.685

Review 8.  Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.

Authors:  Elisabetta Lauretti; Domenico Praticò
Journal:  Expert Opin Ther Targets       Date:  2020-03-06       Impact factor: 6.902

9.  18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases.

Authors:  David N Soleimani-Meigooni; Leonardo Iaccarino; Renaud La Joie; Suzanne Baker; Viktoriya Bourakova; Adam L Boxer; Lauren Edwards; Rana Eser; Maria-Luisa Gorno-Tempini; William J Jagust; Mustafa Janabi; Joel H Kramer; Orit H Lesman-Segev; Taylor Mellinger; Bruce L Miller; Julie Pham; Howard J Rosen; Salvatore Spina; William W Seeley; Amelia Strom; Lea T Grinberg; Gil D Rabinovici
Journal:  Brain       Date:  2020-12-05       Impact factor: 13.501

10.  Alzheimer's-like pathology in aging rhesus macaques: Unique opportunity to study the etiology and treatment of Alzheimer's disease.

Authors:  Amy F T Arnsten; Dibyadeep Datta; Shannon Leslie; Sheng-Tao Yang; Min Wang; Angus C Nairn
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.